Provided by Tiger Fintech (Singapore) Pte. Ltd.

Actinium Pharmaceuticals

1.42
-0.2000-12.35%
Post-market: 1.440.0200+1.41%19:59 EDT
Volume:4.28M
Turnover:6.12M
Market Cap:44.30M
PE:-0.96
High:1.63
Open:1.61
Low:1.42
Close:1.62
Loading ...

Promising Preclinical Results for ATNM-400 Drive Buy Rating for Actinium Pharmaceuticals

TIPRANKS
·
26 Jun

Actinium Pharmaceuticals Price Target Maintained With a $4.00/Share by HC Wainwright & Co.

Dow Jones
·
24 Jun

Actinium Pharmaceuticals Inc - Atnm-400 Shows Superior Efficacy to Xtandi in Prostate Cancer

THOMSON REUTERS
·
23 Jun

Actinium Pharmaceuticals Inc - Reports New Data on Atnm-400 Prostate Cancer Candidate

THOMSON REUTERS
·
23 Jun

Actinium Pharmaceuticals Unveils Promising Preclinical Data for ATNM-400, Showcasing Superior Efficacy in Overcoming Prostate Cancer Treatment Resistance

Reuters
·
23 Jun

ATNM Lawsuit Alert! Class Action Lawsuit Against Actinium Pharmaceuticals

TIPRANKS
·
20 May

Actinium Pharmaceuticals Price Target Maintained With a $4.00/Share by HC Wainwright & Co.

Dow Jones
·
13 May

Actinium Pharmaceuticals Inc - Initial Clinical Data Expected in Second Half of 2025

THOMSON REUTERS
·
06 May

Actinium Announces Enrollment of First Patient in the Iomab-Act Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

THOMSON REUTERS
·
06 May

Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting

PR Newswire
·
28 Apr

Levi & Korsinsky LLP Notifies Shareholders of Actinium Pharmaceuticals, Inc.(ATNM) of a Class Action Lawsuit and an Upcoming Deadline

TIPRANKS
·
03 Apr

Actinium Pharmaceuticals Price Target Maintained With a $4.00/Share by HC Wainwright & Co.

Dow Jones
·
01 Apr

Actinium Pharmaceuticals: Strategic Advancements and Financial Stability Signal Undervalued Opportunity

TIPRANKS
·
29 Mar

Actinium announces positive ATNM-400 results in prostate cancer

TIPRANKS
·
27 Mar

BRIEF-Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225

Reuters
·
27 Mar

Actinium Pharmaceuticals Inc -99.8% Tumor Growth Inhibition Achieved With a Single Dose of Atnm-400 in Preclinical Prostate Cancer Models

THOMSON REUTERS
·
27 Mar

Actinium Pharmaceuticals Announces Atnm-400 a Novel Non-Psma Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225

THOMSON REUTERS
·
27 Mar

Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225

PR Newswire
·
27 Mar

Actinium Pharmaceuticals to Present Business Update at Trump Mar-A-Lago Club Today

PR Newswire
·
26 Mar

Actinium Pharmaceuticals Price Target Maintained With a $4.00/Share by HC Wainwright & Co.

Dow Jones
·
25 Mar